Qingjian (QJ) Wang, PH.D.

Qingjian (QJ) Wang, PH.D.

Position: Executive Director, Nonclinical

Dr. QJ Wang joined Connect in July 2021 to lead the nonclinical programs. He is an experienced pharmacology and toxicology professional with about 30 years of experience working in various capacities in pre/nonclinical drug R&D. Prior to joining the company, he was a Senior Director of R&D at FibroGen, San Francisco. QJ is a key inventor of marketed roxadustat, an innovative first-in-class oral medication utilizing hypoxia-inducible factor (HIF) biology and technique, and Pamrevlumab, a potential first-in-class antibody that inhibits the activity of connective tissue growth factor (CTGF) that is in late-stage Phase 3 clinical development for 3 major indications. He received his Ph.D in Pharmacology and Toxicology at University of California, Davis and completed postdoctoral training in Molecular Biology at University of Tennessee, Memphis.